|
Jan 31
|
Sanofi reports Q4 2024 increase in net income to $916m
|
|
Jan 31
|
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More
|
|
Jan 31
|
Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb
|
|
Jan 31
|
Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...
|
|
Jan 31
|
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
|
|
Jan 30
|
Sanofi (SNY) Q4 2024 Earnings Call Transcript
|
|
Jan 30
|
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
|
|
Jan 30
|
Sanofi: Q4 Earnings Snapshot
|
|
Jan 30
|
Sanofi Plans €5 Billion Buyback, Sees Higher Profit Growth
|
|
Jan 30
|
Sanofi forecasts stronger profit growth, announces €5 billion stock buyback
|
|
Jan 30
|
Sanofi plans share buybacks, signals more deals post Opella sale
|
|
Jan 30
|
Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
|
|
Jan 29
|
Sanofi: Information concerning the total number of voting rights and shares - December 2024
|